Archives
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2018-07
-
SGI-1027 Induces Mitochondrial Apoptosis in Huh7 Liver Cance
2026-07-07
This study demonstrates that SGI-1027, a non-nucleoside DNA methyltransferase inhibitor, induces apoptosis in Huh7 hepatocellular carcinoma cells through the mitochondrial pathway without affecting cell cycle distribution. The findings highlight SGI-1027's utility as an epigenetic modulator for cancer research, particularly in mechanistic studies of tumor suppressor gene reactivation.
-
Applied Use of α-Linolenic Acid in Lipid Metabolism Studies
2026-07-07
α-Linolenic Acid (ALA) is redefining experimental workflows in lipid metabolism, cardiovascular, and immunometabolic research. This guide offers actionable protocols, troubleshooting strategies, and cross-domain insights to optimize bench research using APExBIO's high-purity ALA.
-
Zosuquidar (LY335979) for Reversing Multidrug Resistance in
2026-07-06
Zosuquidar (LY335979) 3HCl is redefining MDR research by providing robust, selective P-glycoprotein inhibition—restoring chemotherapy efficacy in resistant cancer models. This guide delivers actionable protocols and troubleshooting insights, equipping researchers to maximize Zosuquidar’s translational impact across in vitro and in vivo workflows.
-
A 83-01: ALK-5 Inhibitor Advancing TGF-β Pathway Research
2026-07-06
A 83-01, a selective ALK-5 inhibitor from APExBIO, empowers researchers to fine-tune TGF-β signaling in stem cell differentiation and EMT studies. This article spotlights applied workflows, protocol optimization, and troubleshooting strategies to maximize the scientific yield from A 83-01 in diverse experimental settings.
-
Decoding Bacterial Viability: Innovations with the Live-Dead
2026-07-05
Explore the scientific foundations and advanced applications of the Live-Dead Bacterial Staining Kit in bacterial viability assays. This article reveals mechanistic insights and practical strategies that distinguish this tool in modern microbiology research.
-
Cisplatin (A8321): Mechanisms and Benchmarks in Cancer Resea
2026-07-04
Cisplatin (CDDP) is a gold-standard chemotherapeutic agent used extensively in cancer research for its potent DNA crosslinking and apoptosis-inducing properties. Its molecular mechanism, effectiveness in tumor growth inhibition, and unique solubility and stability parameters underpin its value in both in vitro and in vivo models.
-
Alternariol Promotes Hepatic Stellate Cell Activation in Fib
2026-07-03
This study uses omics-based approaches to demonstrate that Alternariol (AOH) and related Alternaria toxins drive hepatic stellate cell transdifferentiation into myofibroblasts, a process underlying liver fibrosis. The findings clarify molecular pathways of toxin-induced liver injury and propose laccase-mediated detoxification as a targeted mitigation strategy.
-
Harnessing Ruxolitinib Phosphate for Advanced JAK/STAT Resea
2026-07-03
This thought-leadership article examines the mechanistic underpinnings and translational promise of Ruxolitinib phosphate (INCB018424) in modulating the JAK/STAT signaling pathway. It synthesizes recent apoptosis and pyroptosis findings in anaplastic thyroid cancer, evaluates competitive and workflow advantages, and provides actionable guidance for researchers seeking to leverage APExBIO’s Ruxolitinib phosphate in disease modeling and drug development.
-
Tofacitinib (CP-690550) for Advanced Immune Cell Assays
2026-07-02
Tofacitinib (CP-690550) empowers researchers to unravel immune modulation by selectively inhibiting JAK1/JAK3-driven cytokine signaling, outperforming conventional anti-cytokine and metabolic interventions in RA macrophage models. This guide distills reference-driven protocols, practical optimization, and troubleshooting for reliable, high-impact immune cell assay results.
-
Carvedilol Phosphate: Mechanisms and Research Applications
2026-07-02
Carvedilol Phosphate is a high-purity, non-selective beta blocker and alpha-1 antagonist used extensively in cardiovascular pharmacology research. Its unique solubility profile and mechanistic versatility enable precise modeling of ischemia–reperfusion injury and GPCR signaling. Uptake of this compound is underpinned by robust physical characterization and recent advances in hepatic IRI models.
-
CKI 7 Dihydrochloride: Next-Gen CK1 Inhibition in Cancer and
2026-07-01
Explore the scientific nuances of CKI 7 dihydrochloride, a potent Casein kinase 1 inhibitor, and its pivotal role in dissecting Wnt signaling, apoptosis, and circadian rhythm regulation. This in-depth article uniquely connects recent kinase research with advanced assay design.
-
Optimizing Cell Assays with α-Linolenic Acid: Scenario-Based
2026-07-01
This article provides an evidence-based, scenario-driven guide to deploying α-Linolenic Acid (SKU C3934) in cell viability, proliferation, and cytotoxicity assays. Drawing on validated protocol parameters and current literature, researchers gain actionable strategies to improve reproducibility and interpretability in lipid metabolism, cardiovascular, and immune modulation studies using high-quality reagents from APExBIO.
-
Vancomycin Hydrochloride in Antibiotic Resistance Assays
2026-06-30
Vancomycin hydrochloride empowers advanced antibiotic resistance and bacterial susceptibility research with precise, reproducible workflows. Explore protocol enhancements and troubleshooting strategies that leverage its unique glycopeptide mechanism for Gram-positive bacterial inhibition.
-
IEM 1460: Selective AMPA Receptor Blocker for Neuroprotectio
2026-06-30
IEM 1460 empowers neuroscience research with reliable, selective AMPA receptor inhibition, enabling robust studies in excitotoxicity and neuroprotection. Its high purity and workflow adaptability make it a top choice for dissecting synaptic transmission and optimizing neuroprotective assays.
-
NSC 87877: Precision SHP2 Inhibition for Neuroinflammation S
2026-06-29
Explore how NSC 87877, a potent SHP2 inhibitor, unlocks advanced neuroinflammation and cancer research. This article delivers insight into its selectivity, mechanisms, and assay protocols, revealing experimental advantages beyond current literature.